Investigational drug · Phase 3
FRSW107
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Severe Hemophilia A.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "FRSW107"
First trial start
2026
Apr 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FRSW107", any sponsor or status.
Conditions studied
As listed on its trial records.
- Severe Hemophilia A
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "FRSW107" as an intervention, largest first.
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.Pivotal-lookingCompleted
Zhengzhou Gensciences IncIndustry
NCT04456387 · 119 participants · Start Oct 15, 2020 · Primary completion Sep 30, 2021
Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection; Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection · For: Hemophilia A
Sites: Hefei, China; Beijing, China; Chongqing, China · 17 sites in all
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia APivotal-lookingCompleted
Zhengzhou Gensciences IncIndustry
NCT04845399 · 101 participants · Start Apr 16, 2021 · Primary completion Jun 26, 2021
Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection · For: Hemophilia A
Sites: Hefei, China; Beijing, China; Chongqing, China · 16 sites in all
- Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia APivotal-lookingNot yet recruiting
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT06136507 · 76 participants (planned) · Start Dec 25, 2026 · Primary completion Dec 31, 2026
Drug: FRSW107 · For: Severe Hemophilia A
Sites: Chongqing, China; Guangzhou, China; Guizhou, China · 13 sites in all
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentPivotal-lookingActive, not recruiting
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT07663903 · 60 participants (planned) · Start Apr 14, 2026 · Primary completion Feb 2027
Drug: FRSW107 · For: Severe Hemophilia A
Sites: Tianjin, China; Fuyang, China; Fuzhou, China · 24 sites in all
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Pivotal-lookingActive, not recruiting
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT07684898 · 60 participants (planned) · Start Jun 12, 2026 · Primary completion Mar 9, 2027
Drug: FRSW107 · For: Severe Hemophilia A
Sites: Tianjin, China; Fuyang, China; Fuzhou, China · 19 sites in all
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT05251090 · 13 participants · Start Jun 16, 2021 · Primary completion Nov 15, 2021
Drug: ADVATE; FRSW107 · For: Hemophilia A
Sites: Beijing, China; Shenzhen, China; Guangzhou, China · 6 sites in all
- A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionStatus unknown
Kaifeng Pharmaceutical (Group) Co., Ltd.Industry
NCT03747653 · 12 participants (planned) · Start Mar 8, 2019 · Primary completion May 31, 2020
Drug: ADVATE; FRSW107 · For: Hemophilia A
Sites: Fuzhou, China; Guangzhou, China; Jinan, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Severe Hemophilia A
- GS1191-0445Phase 32 trials
Gritgen Therapeutics Co., Ltd. · Severe Hemophilia A, Hemophilia A
- FRSW117Recombinant human coagulation factor Ⅷ-Fc fusion proteinPhase 31 trial
Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Severe Hemophilia A
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.